JP2018501215A5 - - Google Patents

Download PDF

Info

Publication number
JP2018501215A5
JP2018501215A5 JP2017529357A JP2017529357A JP2018501215A5 JP 2018501215 A5 JP2018501215 A5 JP 2018501215A5 JP 2017529357 A JP2017529357 A JP 2017529357A JP 2017529357 A JP2017529357 A JP 2017529357A JP 2018501215 A5 JP2018501215 A5 JP 2018501215A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
salt according
salt
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017529357A
Other languages
English (en)
Japanese (ja)
Other versions
JP6550132B2 (ja
JP2018501215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/058965 external-priority patent/WO2016087975A1/en
Publication of JP2018501215A publication Critical patent/JP2018501215A/ja
Publication of JP2018501215A5 publication Critical patent/JP2018501215A5/ja
Application granted granted Critical
Publication of JP6550132B2 publication Critical patent/JP6550132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017529357A 2014-12-03 2015-11-19 Cd38阻害剤及び治療の方法 Active JP6550132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086844P 2014-12-03 2014-12-03
US62/086,844 2014-12-03
PCT/IB2015/058965 WO2016087975A1 (en) 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment

Publications (3)

Publication Number Publication Date
JP2018501215A JP2018501215A (ja) 2018-01-18
JP2018501215A5 true JP2018501215A5 (enExample) 2018-11-01
JP6550132B2 JP6550132B2 (ja) 2019-07-24

Family

ID=54708091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529357A Active JP6550132B2 (ja) 2014-12-03 2015-11-19 Cd38阻害剤及び治療の方法

Country Status (11)

Country Link
US (1) US9840496B2 (enExample)
EP (1) EP3227275B1 (enExample)
JP (1) JP6550132B2 (enExample)
KR (1) KR20170090478A (enExample)
CN (1) CN107428733A (enExample)
AU (1) AU2015356721B2 (enExample)
BR (1) BR112017011642A2 (enExample)
CA (1) CA2969178A1 (enExample)
ES (1) ES2717260T3 (enExample)
RU (1) RU2017121002A (enExample)
WO (1) WO2016087975A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3544612A4 (en) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
BR112021012685A2 (pt) 2019-01-11 2021-12-28 Omeros Corp Métodos para tratar câncer, para aumentar o nível de citocinas th1 nas células mononucleares de sangue periférico humanas, para realçar uma resposta imune antitumoral e para estimular e/ou amplificar uma resposta imune em um sujeito mamífero sofrendo de ou em risco de desenvolver câncer ou metástase de câncer, e, composição farmacêutica
CN119431323A (zh) * 2019-07-31 2025-02-14 贝林格尔·英格海姆国际有限公司 作为cd38抑制剂的杂双环酰胺
WO2021087087A1 (en) 2019-10-30 2021-05-06 Mitobridge Inc. N-cyclohexyl-5-(thiazol-5-yl)-1h-indole-7-carboxamide derivatives and related compounds as cd38 inhibitors for increasing nad+ and for the treatment of e.g. muscular disorders
TW202204331A (zh) 2020-04-07 2022-02-01 美商米突倍基公司 Cd38抑制劑
WO2022077034A1 (en) * 2020-10-09 2022-04-14 Napa Therapeutics Ltd. Heteroaryl amide inhibitors of cd38
PE20232047A1 (es) 2021-01-29 2023-12-27 Boehringer Ingelheim Int Quinolinas y azaquinolinas como inhibidores de cd38
JP2024517750A (ja) * 2021-04-30 2024-04-23 ナンキン イムノファージ バイオテック カンパニー リミテッド 化合物及びそれらのcd38阻害剤としての使用
JP2024525692A (ja) * 2021-07-12 2024-07-12 サイトキネティックス, インコーポレイテッド Cd38調節因子及びその使用方法
WO2024254396A1 (en) * 2023-06-07 2024-12-12 Flagship Pioneering Innovations, Vi, Llc Condensed azines as inhibitors of cyclic adp ribose hydrolase
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433840C (en) * 2001-01-04 2010-05-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
WO2010025235A1 (en) * 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
EP2801573A1 (en) * 2013-05-09 2014-11-12 Sanofi Hydantoine derivatives as CD38 inhibitors

Similar Documents

Publication Publication Date Title
JP2018501215A5 (enExample)
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
JP2017514910A5 (enExample)
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
JP2013032389A5 (enExample)
JP2015537020A5 (enExample)
MX373436B (es) Compuesto peptidico.
JP2016505637A5 (enExample)
EP3954679A3 (en) Amide compounds for the treatment of hiv infections
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
JP2017501237A5 (enExample)
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
JP2017537066A5 (enExample)
JP2016518437A5 (enExample)
MY187617A (en) Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
JP2015024998A5 (enExample)
JP2015516427A5 (enExample)
RU2017121002A (ru) Ингибиторы CD38 и способы лечения
JP2015536325A5 (enExample)
RU2018113718A (ru) Новые соединения
EP4599830A3 (en) Isoxazoline compounds for use in treating demodicosis
JP2016529315A5 (enExample)
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
JP2015521195A5 (enExample)
JP2017529357A5 (enExample)